{Reference Type}: Journal Article
{Title}: Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan.
{Author}: Matsushima H;Taguchi T;Kodama S;Okubo N;Saito K;Jabłońska K;Fukumoto S;Matsumoto T;
{Journal}: J Bone Miner Metab
{Volume}: 42
{Issue}: 2
{Year}: 2024 Mar 17
{Factor}: 2.976
{DOI}: 10.1007/s00774-024-01497-4
{Abstract}: <B>BACKGROUND: </B>Androgen deprivation therapy (ADT) is widely used for the treatment of prostate cancer. ADT is associated with reduced bone density leading to an increased risk of osteoporotic fracture. The objective of this retrospective cohort study was to quantify fracture risk in men treated with ADT for prostate cancer in real-world practice in Japan.<BR><B>METHODS: </B>Data were extracted from the Japanese Medical Data Vision (MDV) database. Men initiating ADT for treatment of prostate cancer between April 2010 and March 2021 were identified and matched to a cohort of prostate cancer patients not taking ADT using a propensity score. Fracture rates were estimated by a cumulative incidence function and compared between cohorts using a Cox cause-specific hazard model. Information was extracted on demographics, comorbidities and bone densitometry.<BR><B>RESULTS: </B>30,561 men with PC starting ADT were matched to 30,561 men with prostate cancer not treated with ADT. Following ADT initiation, <5% of men underwent bone densitometry. Prescription of ADT was associated with an increased fracture risk compared to not taking ADT (adjusted hazard ratio: 1.63 [95% CI 1.52-1.75]).<BR><B>CONCLUSIONS: </B>ADT is associated with a 1.6-fold increase in the risk of osteoporotic fracture in men with prostate cancer. Densitometry in this population is infrequent and monitoring urgently needs to be improved in order to implement effective fracture prevention.